BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Debt
Short-term and long-term borrowings combined.
BioAge Labs, Inc.NASDAQ: BIOA
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 60.9% from a year ago
Total debt stood at $4.03M at the end of Q1 FY2026, down 60.9% from a year earlier and down 27.4% from the prior quarter. Over 3 fiscal years it compounded at +31.1% a year.
Context
- Total debt amounted to 1.0% of total assets at the end of Q1 FY2026, down 2.0 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -60.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 5.56M USD
- Year-over-year change
- -36.1%
- 3-year CAGR
- +31.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.56M | -36.1% |
| FY2024 | 2024-12-31 | 8.7M | -83.7% |
| FY2023 | 2023-12-31 | 53.25M | +2057.7% |
| FY2022 | 2022-12-31 | 2.47M | — |
Total Debt vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -60.9% is the 8th highest of 9, against a peer median of -14.1%.
- Total debt amounts to 1.0% of total assets for BIOA, versus a peer median of 20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$278.71M CAD | -20.0% | -38.7% | 24.9% | |
| Dec 2025 | $142.61M USD | — | — | 61.4% | |
| Mar 2026 | $81.05M USD | -0.3% | -6.3% | 20.5% | |
| Mar 2026 | $71.97M USD | +131.2% | +20.4% | 48.2% | |
| Mar 2026 | $65.9M USD | +315.8% | +9.0% | 59.6% | |
| Mar 2026 | $26.45M USD | -8.1% | +74.1% | 17.9% | |
| Mar 2026 | CA$23.92M CAD | -77.0% | -52.7% | 4.0% | |
| Mar 2026 | $14.66M USD | -50.1% | -29.0% | 14.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $4.03M USD | -60.9% | +31.1% | 1.0% |
| Mar 2026 | $634K USD | -56.1% | -35.4% | 0.2% | |
| Peer median (excluding BIOA) | — | -14.1% | -17.6% | 20.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.